Mission Statement, Vision, & Core Values (2026) of Syncona Limited.

Syncona Limited (listed on the London Stock Exchange as SYNC.L) is a UK-based life sciences investment company whose focused mission-to invest to extend and enhance human life by creating and building companies that deliver transformational treatments in areas of high unmet need-drives a strategy of disciplined capital allocation, risk management and responsible investment; guided by a clear vision to build a portfolio of leading life science companies, Syncona's culture centers on five core values: Excellence, Entrepreneurial spirit, Teamwork, Leadership and being Data-driven, which together shape hands-on engagement with portfolio companies, collaborative partnerships with academia and industry, and a commitment to develop late-stage clinical products that aim to maximize value for patients and stakeholders.

Syncona Limited (SYNC.L) - Intro

• Mission: Extend and enhance human life by creating and growing companies that deliver transformational treatments to patients in areas of high unmet need.
• Vision: Build a diversified portfolio of durable, science‑led companies that redefine standards of care and generate sustainable long‑term value for stakeholders.
• Core values: scientific excellence, patient focus, entrepreneurial rigor, disciplined capital stewardship, transparency and responsible investment.

• Early identification of exceptional science via deep academic and industry networks; active origination with universities and research institutions.
• Hands‑on company creation and incubation: operational teams work alongside management to de‑risk programmes and progress assets to late‑stage clinical development.
• Disciplined capital allocation and risk management: portfolio construction balances high‑upside platform and therapeutic investments with staged funding and governance safeguards.
• Responsible investing and ESG integration: ethical clinical development, patient safety, and sustainability embedded across investment and operating processes.

• Portfolio composition: diversified across gene therapy, cell therapy, biologics and precision medicine platforms, targeting oncology, ophthalmology, rare disease and other high‑unmet need areas.
• Company count: typically ~15-25 active portfolio companies spanning preclinical to commercial stages.
• Clinical progression: multiple programmes in Phase I/II/III and a subset progressing to regulatory submission or partnerships with major biopharma firms.

• Staged funding model: invests in sequential tranches tied to scientific and clinical milestones to preserve capital and align incentives.
• Board and governance: active board representation in portfolio companies, robust scientific advisory panels and external peer review to govern progression decisions.
• Exit pathways: IPOs, strategic partnerships, M&A or royalty/asset sales used to crystallise value for shareholders.

• Academic collaborations: strategic ties with leading universities and translational research centres to source and validate early science.
• Industry partnerships: co‑development and licensing arrangements with larger biopharma organisations to accelerate clinical translation and commercial reach.
• Public and patient engagement: commitment to transparent trial conduct, patient safety and societal impact in therapeutic development.

Syncona Limited (SYNC.L) - Overview

• Focus: company creation and long‑term, patient‑centric build‑outs rather than short‑term trading of assets.
• Therapeutic emphasis: oncology, genetic medicines, ophthalmology, regenerative medicine and other high‑unmet‑need areas.
• Operating model: deep, hands‑on governance, clinical de‑risking, operational support and capital follow‑on to scale promising assets.

• Identify platforms with transformational potential and translate them into clinical programmes.
• Concentrate resources on indications where current standards of care leave meaningful unmet need.
• Engage as an active shareholder to accelerate scientific development, recruit management teams and secure strategic partnerships.

• Active portfolio support: Syncona typically takes board seats and funds multiple follow‑on clinical milestones to de‑risk programmes for patients and partners.
• Partnerships and exits: selective partnerships with biopharma and IPOs/M&A outcomes used to recycle capital into new life‑changing programmes.
• Clinical pipeline impact: several portfolio programmes have advanced into clinical trials addressing oncology, rare genetic disorders and ophthalmic diseases.

• Patient‑first orientation - decisions prioritise clinical impact and unmet need over short‑term financial gain.
• Scientific rigor - deep technical due diligence and ongoing scientific oversight of programmes.
• Long‑term commitment - multiyear capital provision and operational support to scale companies through clinical inflection points.
• Accountability and transparency - public reporting, governance standards and measurable portfolio KPIs guide stewardship.

• Seed and platform funding to bootstrap novel modalities and enable de‑risking to human proof‑of‑concept.
• Targeted follow‑on financings timed to clinical readouts to preserve equity upside while advancing patient benefit.
• Strategic partnering and licence deals to accelerate patient access and broaden development resources.

Syncona Limited (SYNC.L) - Mission Statement

• Patient-centric focus: prioritize indications with significant unmet medical need and potential for durable clinical benefit.
• Company building: partner with founders and management to create independent, sustainable life science businesses.
• Capital commitment: provide multi‑stage, long‑dated capital and follow‑on financing to de‑risk development pathways.
• Scientific rigor: invest where deep science and compelling translational data support a clear clinical development plan.
• Commercial discipline: combine scientific ambition with disciplined portfolio and capital allocation decisions.

• Strategic investments and partnerships: leverage in‑house expertise and external networks to accelerate development.
• Frontier technologies: focus on modalities (e.g., gene therapy, cell therapy, precision biologics) with potential for step‑change outcomes.
• Sustainable growth: align scientific milestones with financing strategies to preserve upside for patients and shareholders.

• Hands‑on company building: governance, talent recruitment, regulatory and clinical strategy support.
• Flexible capital deployment: seed, growth, IPO support and exit readiness to optimize each company's pathway.
• Network effects: access to academic spin‑outs, strategic partners, and specialist service providers in biotech ecosystems.
• Outcome alignment: structures that align management, founders and Syncona on long‑term patient and shareholder value.

Syncona Limited (SYNC.L) - Vision Statement

• Focused mission: translate deep science into healthcare interventions that materially improve patient outcomes.
• Investment horizon: patient, evidence-led company building with multi-year value creation trajectories.
• Dual returns: clinically meaningful medicines alongside attractive risk-adjusted financial returns.

• Excellence - continual pursuit of best outcomes for patients, investors and partners; high expectations, integrity and robust governance.
• Entrepreneurial - active external engagement, curiosity, creativity, and readiness to take measured risks with urgency and bravery.
• Teamwork - diverse talent and perspectives, open feedback, collaboration and transparency across investment and operating teams.
• Leadership - ownership, independent thinking, empowerment, resilience and sustained drive to de‑risk and scale portfolio companies.
• Data-driven - relentless search for data, hypothesis testing, evidence-based decisions and intellectual honesty with constructive challenge.

• Excellence - KPI: proportion of portfolio companies reaching clinical milestones (IND/CTA submissions, Phase I/II starts); target: accelerate proof‑of‑concept events.
• Entrepreneurial - KPI: number of new company formations per year and time-to-first-infusion/first‑clinical-readout; emphasis on rapid de‑risking.
• Teamwork - KPI: cross-functional management appointments, retention metrics, and employee engagement scores driving company operational strength.
• Leadership - KPI: board placements, CEO performance benchmarks, and demonstrated follow‑on financing success.
• Data-driven - KPI: adoption of data packages to support go/no‑go decisions, percentage of investment decisions with quantified probabilistic models.

• Active company building - deploying capital and operating expertise to lead rounds, recruit management and establish clinical development plans.
• Data-first decisions - clinical and translational data guide portfolio prioritisation and resource allocation; hypotheses tested with clear go/no‑go criteria.
• Collaborative partnerships - co-investments and strategic alliances with academic centres and pharma to accelerate development and de‑risk assets.